Expression of the Bcl-3 proto-oncogene suppresses p53 activation

Genes and Development

Volumn 20, Issue 2, 2006, Pages 225-235

  Kashatus, David ^a   Cogswell, Patricia ^a   Baldwin, Albert S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Bcl 3; Hdm2; NF B; p53

Indexed keywords

PROTEIN BCL 3; PROTEIN P53;

ANIMAL CELL; APOPTOSIS; ARTICLE; CARCINOGENIC ACTIVITY; CELL CYCLE ARREST; CONTROLLED STUDY; DNA DAMAGE; EMBRYO; GENE; GENE EXPRESSION; GENE FUNCTION; GENE HDM 2; GENE INDUCTION; GENE SWITCHING; GERMINAL CENTER; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; SOMATIC HYPERMUTATION; UPREGULATION;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL CYCLE; DNA DAMAGE; EMBRYO; FIBROBLASTS; GENE EXPRESSION REGULATION; GERM-LINE MUTATION; GERMINAL CENTER; MICE; NF-KAPPA B; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; RECOMBINATION, GENETIC; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

ANIMALIA;

EID: 30944468153     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.1352206     Document Type: Article

References (53)

1. Barak, Y., Juven, T., Haffner, R., and Oren, M. 1993. mdm2 expression is induced by wild type p53 activity. EMBO J. 12: 461-468.
2. Bond, G.L., Hu, W., Bond, E.E., Robins, H., Lutzker, S.G., Arva, N.C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. 2004. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591-602.
3. Bond, G.L., Hu, W., and Levine, A.J. 2005. MDM2 is a central node in the p53 pathway: 12 years and counting. Curr. Cancer Drug Targets 5: 3-8.
4. Boulton, S.J., Gartner, A., Reboul, J., Vaglio, P., Dyson, N., Hill, D.E., and Vidal, M. 2002. Combined functional genomic maps of the C. elegans DNA damage response. Science 295: 127-131.
5. Bours, V., Franzoso, G., Azarenko, V., Park, S., Kanno, T., Brown, K., and Siebenlist, U. 1993. The oncoprotein Bcl-3 directly transactivates through κ B motifs via association with DNA-binding p50B homodimers. Cell 72: 729-739.
6. Brasier, A.R., Lu, M., Hai, T., Lu, Y., and Boldogh, I. 2001. NF-κ B-inducible BCL-3 expression is an autoregulatory loop controlling nuclear p50/NF-κ B1 residence. J. Biol. Chem. 276: 32080-32093.
7. Canoz, O., Rassidakis, G.Z., Admirand, J.H., and Medeiros, L.J. 2004. Immunohistochemical detection of BCL-3 in lymphoid neoplasms: A survey of 353 cases. Mod. Pathol. 17: 911-917.
8. Chipuk, J.E., Kuwana, T., Bouchier-Hayes, L., Droin, N.M., Newmeyer, D.D., Schuler, M., and Green, D.R. 2004. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303: 1010-1014.
9. Cogswell, P.C., Guttridge, D.C., Funkhouser, W.K., and Baldwin Jr., A.S. 2000. Selective activation of NF-κ B subunits in human breast cancer: Potential roles for NF-κ B2/p52 and for Bcl-3. Oncogene 19: 1123-1131.
10. Dechend, R., Hirano, F., Lehmann, K., Heissmeyer, V., Ansieau, S., Wulczyn, F.G., Scheidereit, C., and Leutz, A. 1999. The Bcl-3 oncoprotein acts as a bridging factor between NF-κB/Rel and nuclear co-regulators. Oncogene 18: 3316-3323.
11. el-Deiry, W.S., Tokino, T., Velculescu, V.E., Levy, D.B., Parsons, R., Trent, J.M., Lin, D., Mercer, W.E., Kinzler, K.W., and Vogelstein, B. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
12. Espinosa, J.M., Verdun, R.E., and Emerson, B.M. 2003. p53 functions through stress- and promoter-specific recruitment of transcription initiation components before and after DNA damage. Mol. Cell 12: 1015-1027.
13. Franzoso, G., Carlson, L., Scharton-Kersten, T., Shores, E.W., Epstein, S., Grinberg, A., Tran, T., Shacter, E., Leonardi, A., Anver, M., et al. 1997. Critical roles for the Bcl-3 oncoprotein in T cell-mediated immunity, splenic microarchitecture, and germinal center reactions. Immunity 6: 479-490.
14. Ghosh, S. and Karin, M. 2002. Missing pieces in the NF-κB puzzle. Cell 109(Suppl): S81-S96.
15. Hay, T.J. and Meek, D.W. 2000. Multiple sites of in vivo phosphorylation in the MDM2 oncoprotein cluster within two important functional domains. FEBS Lett. 478: 183-186.
16. Hayden, M.S. and Ghosh, S. 2004. Signaling to NF-κB. Genes & Dev. 18: 2195-2224.
17. Hubinger, G., Muller, E., Scheffrahn, I., Schneider, C., Hildt, E., Singer, B.B., Sigg, I., Graf, J., and Bergmann, L. 2001. CD30-mediated cell cycle arrest associated with induced expression of p21(CIP1/WAF1) in the anaplastic large cell lymphoma cell line Karpas 299. Oncogene 20: 590-598.
18. Issaeva, N., Bozko, P., Enge, M., Protopopova, M., Verhoef, L.G., Masucci, M., Pramanik, A., and Selivanova, G. 2004. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 10: 1321-1328.
19. Jeffers, J.R., Parganas, E., Lee, Y., Yang, C., Wang, J., Brennan, J., MacLean, K.H., Han, J., Chittenden, T., Ihle, J.N., et al. 2003. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 4: 321-328.
20. Komarov, P.G., Komarova, E.A., Kondratov, R.V., Christov-Tselkov, K., Coon, J.S., Chernov, M.V., and Gudkov, A.V. 1999. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285: 1733-1737.
21. Kucharczak, J., Simmons, M.J., Fan, Y., and Gelinas, C. 2003. To be, or not to be: NF-κB is the answer: Role of Rel/NF-κB in the regulation of apoptosis. Oncogene 22: 8961-8982.
22. -ΔΔ(T) method. Methods 25: 402-408.
23. Mayo, L.D., Turchi, J.J., and Berberich, S.J. 1997. Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. Cancer Res. 57: 5013-5016.
24. Mayo, M.W., Wang, C.Y., Cogswell, P.C., Rogers-Graham, K.S., Lowe, S.W., Der, C.J., and Baldwin Jr., A.S. 1997. Requirement of NF-κB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 278: 1812-1815.
25. McKeithan, T.W., Rowley, J.D., Shows, T.B., and Diaz, M.O. 1987. Cloning of the chromosome translocation breakpoint junction of the t(14;19) in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. 84: 9257-9260.
26. Mitchell, T.C., Hildeman, D., Kedl, R.M., Teague, T.K., Schaefer, B.C., White, J., Zhu, Y., Kappler, J., and Marrack, P. 2001. Immunological adjuvants promote activated T cell survival via induction of Bcl-3. Nat. Immunol. 2: 397-402.
27. Momand, J., Jung, D., Wilczynski, S., and Niland, J. 1998. The MDM2 gene amplification database. Nucleic Acids Res. 26: 3453-3459.
28. Na, S.Y., Choi, H.S., Kim, J.W., Na, D.S., and Lee, J.W. 1998. Bcl3, an IκB protein, as a novel transcription coactivator of the retinoid X receptor. J. Biol. Chem. 273: 30933-30938.
29. Nakano, K. and Vousden, K.H. 2001. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 7: 683-694.
30. Nishikori, M., Maesako, Y., Ueda, C., Kurata, M., Uchiyama, T., and Ohno, H. 2003. High-level expression of BCL3 differentiates t(2;5)(p23;q35)-positive anaplastic large cell lymphoma from Hodgkin disease. Blood 101: 2789-2796.
31. Nolan, G.P., Fujita, T., Bhatia, K., Huppi, C., Liou, H.C., Scott, M.L., and Baltimore, D. 1993. The bcl-3 proto-oncogene encodes a nuclear I κ B-like molecule that preferentially interacts with NF-κ B p50 and p52 in a phosphorylation-dependent manner. Mol. Cell. Biol. 13: 3557-3566.
32. Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., Tokino, T., Taniguchi, T., and Tanaka, N. 2000. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288: 1053-1058.
33. Phan, R.T. and Dalla-Favera, R. 2004. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 432: 635-639.
34. Phelps, M., Darley, M., Primrose, J.N., and Blaydes, J.P. 2003. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor α-positive breast cancer cells. Cancer Res. 63: 2616-2623.
35. Rocha, S., Martin, A.M., Meek, D.W., and Perkins, N.D. 2003. p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-κB subunit with histone deacetylase 1. Mol. Cell. Biol. 23: 4713-4727.
36. Ryan, K.M., Ernst, M.K., Rice, N.R., and Vousden, K.H. 2000. Role of NF-κB in p53-mediated programmed cell death. Nature 404: 892-897.
37. Schwarz, E.M., Krimpenfort, P., Berns, A., and Verma, I.M. 1997. Immunological defects in mice with a targeted disruption in Bcl-3. Genes & Dev. 11: 187-197.
38. Slack, A., Chen, Z., Tonelli, R., Pule, M., Hunt, L., Pession, A., and Shohet, J.M. 2005. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc. Natl. Acad. Sci. 102: 731-736.
39. Suzuki, K., Yokoyama, S., Waseda, S., Kodama, S., and Watanabe, M. 2003. Delayed reactivation of p53 in the progeny of cells surviving ionizing radiation. Cancer Res. 63: 936-941.
40. Tergaonkar, V., Pando, M., Vafa, O., Wahl, G., and Verma, I. 2002. p53 stabilization is decreased upon NFκB activation: A role for NFB in acquisition of resistance to chemotherapy. Cancer Cell 1: 493-503.
41. Thornburg, N.J., Pathmanathan, R., and Raab-Traub, N. 2003. Activation of nuclear factor-κB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma. Cancer Res. 63: 8293-8301.
42. Viatour, P., Bentires-Alj, M., Chariot, A., Deregowski, V., de Leval, L., Merville, M.P., and Bours, V. 2003. NF-κ B2/p100 induces Bcl-2 expression. Leukemia 17: 1349-1356.
43. Viatour, P., Dejardin, E., Warnier, M., Lair, F., Claudio, E., Bureau, F., Marine, J.C., Merville, M.P., Maurer, U., Green, D., et al. 2004. GSK3-mediated BCL-3 phosphorylation modulates its degradation and its oncogenicity. Mol. Cell 16: 35-45.
44. Villunger, A., Michalak, E.M., Coultas, L., Mullauer, F., Bock, G., Ausserlechner, M.J., Adams, J.M., and Strasser, A. 2003. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 302: 1036-1038.
45. Vousden, K.H. and Lu, X. 2002. Live or let die: The cell's response to p53. Nat. Rev. Cancer 2: 594-604.
46. Vousden, K.H. and Prives, C. 2005. P53 and prognosis: New insights and further complexity. Cell 120: 7-10.
47. Wan, Y.Y. and DeGregori, J. 2003. The survival of antigenstimulated T cells requires NFκB-mediated inhibition of p73 expression. Immunity 18: 331-342.
48. Watanabe, N., Wachi, S., and Fujita, T. 2003. Identification and characterization of BCL-3-binding protein: Implications for transcription and DNA repair or recombination. J. Biol. Chem. 278: 26102-26110.
49. Webster, G.A. and Perkins, N.D. 1999. Transcriptional cross talk between NF-κB and p53. Mol. Cell Biol. 19: 3485-3495.
50. Wessells, J., Baer, M., Young, H.A., Claudio, E., Brown, K., Siebenlist, U., and Johnson, P.F. 2004. BCL-3 and NF-κB p50 attenuate lipopolysaccharide-induced inflammatory responses in macrophages. J. Biol. Chem. 279: 49995-50003.
51. Westerheide, S.D., Mayo, M.W., Anest, V., Hanson, J.L., and Baldwin Jr., A.S. 2001. The putative oncoprotein Bcl-3 induces cyclin D1 to stimulate G(1) transition. Mol. Cell. Biol. 21: 8428-8436.
52. Yu, J., Zhang, L., Hwang, P.M., Kinzler, K.W., and Vogelstein, B. 2001. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell 7: 673-682.
53. Zhang, Y., Xiong, Y., and Yarbrough, W.G. 1998. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725-734.